ArticleBMC neuroscience2025
Pro-cognitive efficacy of Prospekta in a rat model of age-associated cognitive impairment.
Article in BMC neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Effect of Frequency of Prospekta Administration: Anxiolytic Effect in Wistar Rats.Dose-response : a publication of International Hormesis SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAgeing is associated with lower levels of cognitive performance, and novel therapeutics are warranted to correct this defect. Aged rats represent a favourable model of human ageing. The aim of the present study is to examine the effect of a novel neurotropic S100B-targeted drug, Prospekta, on the parameters of delayed alternation in the aged rats compared to responses in the young animals.
methodsA spatial working memory task in an operant chamber, where aged and young animals (21 and 2 months old, respectively) needed to alternate between two retractable levers on a trial-by-trial basis to receive a food reward, was tested. We also assessed the Prospekta's effect on expression of some biomarkers of ageing by measuring their levels in the brains of aged rats using Western blot.
resultsTreatment with Prospekta ameliorated cognitive functions, which resulted in a significant reduction of simple and choice reaction times for aged rats. The drug also decreased the number of omission errors at the beginning of the acquisition phase, which indicated the influence of treatment on attention and decision-making process. At the same time, Prospekta did not affect the majority of parameters measured in young animals. The analysis of ageing biomarker expression did not reveal any significant differences between aged rats treated with Prospekta or placebo.
conclusionsThe findings of this study underscore the potential of Prospekta as a promising pro-cognitive agent for the treatment of age-related cognitive decline. However, further research is imperative to elucidate the precise mechanisms underlying its therapeutic effects and validate its efficacy in vivo. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.